Treffer 1 - 3 von 3 für Suche 'Pover, Gillian M', Suchdauer: 0,42s Treffer weiter einschränken
  1. 1
    A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

    A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal... von Bennouna, Jaafar, Lang, Istvan, Valladares-Ayerbes, Manuel, Boer, Katalin, Adenis, Antoine, Escudero, Pilar, Kim, Tae-You, Pover, Gillian M., Morris, Clive D., Douillard, Jean-Yves

    Veröffentlicht in Investigational new drugs

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

    Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study von Boér, Katalin, Láng, István, Llombart-Cussac, Antonio, Andreasson, Inger, Vivanco, Guillermo L., Sanders, Nick, Pover, Gillian M., Murray, Elizabeth

    Veröffentlicht in Investigational new drugs

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer

    A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer von Horti, József, Widmark, Anders, Stenzl, Arnulf, Federico, Miriam H, Abratt, Raymond P, Sanders, Nick, Pover, Gillian M, Bodrogi, István


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: